Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 43.2063
- Book/Share 64.2129
- PB 7.1149
- Debt/Equity 0.1
- CurrentRatio 2.6456
- ROIC -0.128
- MktCap 117322845390.0
- FreeCF/Share -4.8968
- PFCF -93.2614
- PE -118.6873
- Debt/Assets 0.0721
- DivYield 0
- ROE -0.0625
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
| Downgrade | VRTX | Oppenheimer | Outperform | Perform | -- | -- | Dec. 19, 2024 |
| Upgrade | VRTX | Jefferies | Hold | Buy | $500 | $550 | Dec. 9, 2024 |
| Initiation | VRTX | Scotiabank | -- | Sector Perform | -- | -- | Oct. 16, 2024 |
News
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day.
Read More
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology. “We are honored to be recognized at Premier's 2025.
Read More
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term data shows durable, life-changing benefits for SCD and TDT patients, but adoption is limited by a complex, intensive treatment process. Current Casgevy revenues are modest, but improvements to preconditioning and in-vivo approaches could unlock blockbuster potential by 2030.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Read More
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
Read More
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential b.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript
Published: June 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Participant Michael Rickels - Corporate Participant Felicia Pagliuca - Corporate Participant Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Bryan Russell Dollinger - Leerink Partners LLC, Research Division Dina Elmonshed - Jefferies LLC, Research Division Jarwei Fang - Unidentified Company Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mohit Bansal - Wells …
Read More
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Negative
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Call Participants Will Pickering - Bernstein Will Pickering All right. Well, I think we can get started.
Read More
3 Top Growth Stocks to Buy in the Second Half of 2025
Published: May 26, 2025 by: The Motley Fool
Sentiment: Positive
Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.
Read More
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts.
Read More
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
Published: May 09, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top names to watch for the second half.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
Read More
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Read More
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Published: May 06, 2025 by: Benzinga
Sentiment: Negative
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.
Read More
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Read More
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.
Published: May 06, 2025 by: Barrons
Sentiment: Negative
The company discloses narrower-than-expected access to its new painkiller.
Read More
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
Published: May 06, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell.
Read More
2 Pharma Stocks Staging Big Post-Earnings Moves
Published: May 06, 2025 by: Schaeffers Research
Sentiment: Neutral
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani FASN,
- Employees 6100